President Trump delivers remarks on lowering the prices of drugs and pharmaceuticals

President Trump delivers remarks on lowering the prices of drugs and pharmaceuticals

Novartis CEO Vasant Nrasimhan delivers remarks, following US President Donald Trump’s remarks on lowering the prices of drugs and pharmaceuticals during an announcement in the Roosevelt Room of the White House in Washington, DC, USA, 19 December 2025.

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

President Macron Meets Novartis CEO Vasant Narasimhan - Versailles

Novartis CEO Vasant Narasimhan and French President Emmanuel Macron during the seventh "Choose France Summit", aiming to attract foreign investors to the country, at the Chateau de Versailles, near Paris, on May 13, 2024. Photo by Eliot Blondet/ABACAPRESS.COM

Novartis headquarters

Novartis headquarters

File photo taken Jan. 27, 2024, shows the headquarters of Swiss pharmaceutical company Novartis AG in Basel.

(CIIE)CHINA-SHANGHAI-CIIE-PRODUCTS (CN)

(CIIE)CHINA-SHANGHAI-CIIE-PRODUCTS (CN)

(231110) -- SHANGHAI, Nov. 10, 2023 (Xinhua) -- Participants learn product information through VR devices at a booth of Novartis at the 6th China International Import Expo (CIIE) in east China's Shanghai, Nov. 5, 2023. (Xinhua/Wang Xiang)

Ex-Novartis Pharma employee arrested over drug data

Ex-Novartis Pharma employee arrested over drug data

TOKYO, Japan - Health, Labor and Welfare Minister Norihisa Tamura responds to questions by reporters at the Diet building in Tokyo, Japan, after Tokyo prosecutors arrested a former employee of Novartis Pharma K.K. on June 11, 2014, on a charge of manipulating clinical study data leading to exaggerated claims in advertising for one of the firm's drugs.

Ex-Novartis Pharma employee arrested over drug data

Ex-Novartis Pharma employee arrested over drug data

TOKYO, Japan - Photo taken on June 11, 2014, shows a building that houses Novartis Pharma K.K. in Tokyo's Minato Ward. Tokyo prosecutors arrested a former employee of the company the same day on a charge of manipulating clinical study data leading to exaggerated claims in advertising for one of the firm's drugs.

Novartis management replaced

Novartis management replaced

TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.

Novartis management replaced

Novartis management replaced

TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.

Novartis management replaced

Novartis management replaced

TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.

Novartis Pharma accused over drug ads

Novartis Pharma accused over drug ads

TOKYO, Japan - Health, Labor and Welfare Ministry officials hold a press conference at the ministry in Tokyo on Jan. 9, 2014, after filing a criminal complaint with prosecutors against Novartis Pharma K.K. over alleged exaggerated advertising for a blood pressure-lowering drug.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis scandal

Novartis scandal

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis division head Epstein

Novartis division head Epstein

TOKYO, Japan - David Epstein, division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks with reporters after holding talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.

Novartis Pharma

Novartis Pharma

TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.

Data altered in Japanese research for Novartis blood pressure drug

Data altered in Japanese research for Novartis blood pressure drug

TOKYO, Japan - Toshikazu Yoshikawa (2nd from L), president of the Kyoto Prefectural University of Medicine, and Shinji Fushiki (L), the university窶冱 vice president, bow toward the end of a press conference in Kyoto on July 11, 2013. Yoshikawa apologized as the university found that data employed in a clinical study on Novartis Pharama K.K.'s blockbuster blood pressure lowering drug Diovan were manipulated.

Novartis Japan unit faces business suspension order

Novartis Japan unit faces business suspension order

Photo taken June 12, 2014, shows the building in Tokyo's Minato Ward housing a Japanese unit of Swiss pharmaceutical maker Novartis AG. The health ministry has decided to order a business suspension of around 15 days for the Tokyo-based company for not reporting serious side effects of its drugs, sources close to the matter said on Feb. 2, 2015. (Kyodo) ==Kyodo

Novartis Pharma unveils preventive measures against misconduct

Novartis Pharma unveils preventive measures against misconduct

Dirk Kosche, president of Novartis Pharma K.K., the Japanese unit of Swiss pharmaceutical maker Novartis AG, bows in apology during a press conference in Tokyo on June 9, 2015. Kosche unveiled measures to prevent the reoccurrence of company misconduct involving not reporting serious side effects of its drugs. (Kyodo) ==Kyodo